Revised. Amendments from Version 1
==================================

In response to the peer review, the following changes were made: - A paragraph (paragraph two under 'Search strategy') has been added to provide more detail on the scoping search. -  A sentence has been added ( last sentence of paragraph one under 'screening')  to clarify which processes will be used for full text inclusion.  - A new sentence has been added (at the end of paragraph three under 'data extraction and analysis') to clarify that italics will be used for first order data - We have added sentences to clarify what each of the four CERQual domains assess (amended paragraph under 'Assessing the quality of the body of evidence', added after sentence three).

Introduction
============

Chronic disease has become one of the biggest challenges for healthcare systems globally ^[@ref-1]^. This has brought into focus the phenomenon of multimorbidity, the presence of two or more chronic diseases in a patient ^[@ref-2]^. Multimorbidity is of increasing concern due to the high disease burden and the related high rates of healthcare utilisation. The estimated prevalence of multimorbidity in the general population ranges from 13% to 72% ^[@ref-2]^. These variations are largely accounted for by differences in settings and age groups across prevalence studies. The prevalence is likely increasing due to the ageing of the population globally ^[@ref-3]^. Despite this, healthcare systems internationally are primarily single disease focused ^[@ref-4]^. This single disease focus is reflected in clinical guidelines, which primarily treat diseases in isolation and rarely account for patients with multimorbidity. This creates a significant treatment burden ^[@ref-4]^ which has several consequences for patients with multimorbidity, including a financial burden.

Financial burden refers to direct medical costs, direct non-medical costs and indirect-costs accruing to patients as a result of their multimorbidity. The financial burden of multimorbidity on patients is widespread and can be significant. A systematic review of cost-of-illness studies concluded that multimorbidity was always associated with higher out-of-pocket (OOP) expenditure than single or no chronic conditions ^[@ref-5]^. Another systematic review found that a greater number of conditions present in a person was associated with higher OOP expenditure on medications ^[@ref-6]^. This financial burden is of particular concern in terms of equity, as multimorbidity disproportionately affects patients from lower socioeconomic groups ^[@ref-7]^.

Much of this economic-burden associated with multimorbidity arises from OOP expenditure or direct medical costs but it may also arise from direct non-medical costs including transportation to healthcare appointments and indirect costs including work absences. The economic-burden associated with multimorbidity can have negative effects including reduced medication adherence primarily due to inability to purchase required medication ^[@ref-6]^, impoverishing spending (i.e., spending that pushes a household below an agreed poverty line) ^[@ref-5]^, and reduced quality-of-life ^[@ref-5]^.

Several qualitative studies have examined patients' lived experience of multimorbidity ^[@ref-8],\ [@ref-9]^. Many of these studies have a brief focus on experience of financial burden. By synthesising these studies, a broader picture of this experience can be provided. It has been suggested that by synthesising many studies the patient is given a greater voice ^[@ref-10]^. The authors therefore sought to synthesise qualitative research exploring experience of financial burden for patients with multimorbidity.

Research questions
==================

What are the experiences of patients with multimorbidity of financial burden?

How does financial burden affect interactions between patients with multimorbidity and the healthcare system?

How does financial burden impact on treatment burden for patients with multimorbidity?

Methods
=======

Design
------

There are recognised challenges in upholding the complexity and context of primary qualitative research when conducting a qualitative systematic review. However, patients' views and experiences should inform decision making ^[@ref-11]^ and these can be ascertained using qualitative methods ^[@ref-11]^. By providing a systematic review and synthesis of this research, policy-makers can be more comprehensively informed ^[@ref-11]^.

This review will be conducted and reported using the ENTREQ guidelines ^[@ref-12]^. The review protocol is written in accordance with the PRISMA-P guidelines (reporting guidelines ^[@ref-13]^).

Search strategy
---------------

The following databases will be searched: [Lilacs](http://lilacs.bvsalud.org/en/), [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/), [CINAHL](https://www.ebscohost.com/nursing/products/cinahl-databases/cinahl-complete), [EMBASE](https://www.embase.com/login), [PsycINFO](https://www.apa.org/pubs/databases/psycinfo/), and [Applied Social Sciences Index and Abstracts](https://www.proquest.com/products-services/ASSIA-Applied-Social-Sciences-Index-and-Abstracts.html). Additionally, forward and backward citation checking of included studies will be conducted. Content experts will be contacted requesting information on any articles the content experts feel are relevant. For the grey-literature search a list of websites considered relevant by the research team were chosen (extended data ^[@ref-13]^). Databases will be searched from inception using combinations of Mesh terms and key-words (extended data ^[@ref-13]^).

The search strategy was developed in conjunction with a librarian. Scoping searches were conducted using key words related to financial burden and qualitative research. The terms for multimorbidity were taken from the Cochrane systematic review examining multimorbidity interventions ^[@ref-13]^. The search strategy presented in extended data ^[@ref-13]^ is based on Medline and will be tested and adapted for all other databases.

Screening
---------

Search results will be exported to [Endnote](https://endnote.com/) X8, duplicate entries removed and then imported into [Covidence](https://www.covidence.org/home). For step one, titles will be screened by a single reviewer (JL) to remove entries that are clearly unrelated to the research question. For step two, two reviewers (JL, LF) will screen titles and abstracts independently; according to the inclusion criteria ( [Table 1](#T1){ref-type="table"}). Any disagreements will be resolved through discussion. If this does not lead to agreement, then a third reviewer will decide on inclusion for full-text review. Potentially eligible full texts will be independently evaluated by two reviewers (JL, LF) against the inclusion and exclusion criteria and disagreement will be managed by a third reviewer (SS).

###### Inclusion and exclusion criteria based on modified PICoS ^[@ref-15]^.

  ------------------------------------------------------------------------------------------------------------------------
  PICoS                        Inclusion Criteria                                      Exclusion Criteria
  ---------------------------- ------------------------------------------------------- -----------------------------------
  **Population**               Identified as patient with multimorbidity\              Single condition focus
                               ≥ 2 chronic diseases\                                   
                               Community dwelling adults (≥ 18 years old)              

  **Phenomenon of Interest**   Financial burden for patients                           

  **Context**                  Any country\                                            Residential healthcare facilities
                               Primary and secondary care                              

  **Study Type**               Qualitative\                                            Quantitative
                               Original research (e.g., interviews or focus groups)\   
                               Mixed methods                                           
  ------------------------------------------------------------------------------------------------------------------------

Eligibility criteria
--------------------

Only studies using a qualitative design, with primary data collection, referencing experiences of financial burden, and examining community-dwelling adults (≥ 18 years) with multimorbidity will be included ( [Table 1](#T1){ref-type="table"}). Studies examining patients with non-specific chronic disease will be included if they include patients with multimorbidity and do not have a single condition focus. Qualitative design refers to studies which use a method of data collection and data analysis which are recognised qualitative methods ^[@ref-14]^, for example interviews, focus groups, thematic analysis, and content analysis. Financial burden refers to the direct medical costs, direct non-medical costs and indirect costs experienced by patients. It is expected that the focus of studies will not exclusively be financial burden. Therefore, papers with broader focuses, such as the experience of multimorbidity, will be reviewed for inclusion. Also, many studies concerning financial burden and multimorbidity relate to polypharmacy, therefore studies concerning the experience of polypharmacy for patients with multimorbidity will be included if they meet the inclusion criteria. Studies without reference to financial burden will be excluded. Only data related to experience of financial burden for patients with multimorbidity will be included in the analysis. Mixed-methods studies with primary qualitative data collection will be included if they meet the inclusion criteria and where it is possible to extract the findings derived from the qualitative research. No language restrictions will apply.

Data extraction and analysis
----------------------------

Two reviewers will extract study characteristics independently using a proforma (see extended data ^[@ref-13]^) under the following headings: setting, country, year of publication, methodology, participants (age, gender, socioeconomic status, conditions), sampling strategy, data-analysis technique, and definition of financial burden. Conflicts will be resolved by a third reviewer (BC).

Data (quotes, themes and author interpretations) will be extracted verbatim from the results section of included studies. This process will be conducted by a single reviewer (JL), and then cross-checked by a second reviewer (LF) to increase confirmability. Only data considered relevant to the research questions will be extracted. If information is unavailable from the full-text, then the corresponding author will be contacted for clarification. If there is no reply, then a follow-up email will be sent one week later and if no reply is received within one week of the second email then a decision will be made on inclusion based on information available.

Thematic-synthesis, as described by Thomas and Harden ^[@ref-16]^, will be used. Thematic-synthesis is an inductive approach which is often used for studies with 'thin' data and analysis ^[@ref-16]^. It is also used to draw inference based on common themes from studies with different designs and perspectives ^[@ref-17]^. Thematic-synthesis consists of a three step process; step one consists of line-by-line coding of the data of included studies. The second step involves organisation or grouping these codes into related areas to construct 'descriptive' themes. In step three, the descriptive themes will be iteratively examined and compared to refine the relationship between them and generate analytical themes that is, themes that go beyond the descriptive themes to provide new insights related to the review question. Data will be coded using [NVIVO](https://www.qsrinternational.com/nvivo/nvivo-products) version 12. Following multiple readings of the included papers data-analysis will be carried out by a single reviewer (JL) following the three steps outlined above. In order to increase confirmability of the analysis, all studies will be independently read by a second reviewer (LF) to crosscheck the coding structure and themes developed. This process will be overseen by a third reviewer (BC). In order to increase the credibility of the findings, an overview of the results will be brought for discussion to a panel of public and patient representatives with experience of multimorbidity. Direct quotations from study participants will be presented in italics to distinguish them from second order data (author interpretations).

Quality-appraisal of included studies
-------------------------------------

The critical appraisal skills programme (CASP) checklist for qualitative research ^[@ref-18]^ will be used to assess the methodological quality of all included studies. Two reviewers (JL and LF) will independently evaluate each study and any differences will be resolved through discussion. If this does not lead to agreement, then a third reviewer (BC) will adjudicate. Studies will not be excluded based on quality-appraisal. Quality-appraisal will be used as a means of discussing the quality of the included studies and to inform the GRADE CERQual (Confidence in the Evidence from Reviews of Qualitative research) assessment of confidence in the review findings ^[@ref-19]^.

Assessing the quality of the body of evidence
---------------------------------------------

The review is intended to form part of a project which will inform how the specific needs of patients with multimorbidity are considered within clinical guidelines in Ireland. Therefore, the GRADE CERQual approach will be used to summarise our confidence in the evidence ^[@ref-19]^. Four components contribute to an assessment of confidence in the evidence for an individual review finding: methodological limitations, relevance, coherence, and adequacy of data. Methodological limitations assesses the conduct and design of the primary studies in relation to the findings to which they are contributing. Relevance assesses the degree to which the evidence from the primary studies applies to the context of the review question. Coherence assesses how well the findings are supported by and fit with the primary studies. Adequacy of data assesses how much data supports a finding and how rich this data is. Confidence in the evidence will be graded as high, moderate, low, or very low. This assessment will also be conducted in duplicate (JL and LF) and discussed amongst the research team.

***Reflexivity***. It is important to consider all findings in the context of research team members' personal worldviews and experiences. Three authors have a background in social science; in psychology (JL, LF) and sociology and health services research (BC). One author has a background in general practice (SS) and is a leading expert in multimorbidity research, and one has a background in pharmacy and health economics (PH). The authors have operated within the Irish and other healthcare contexts. In relation to analysis, the lead researcher conducting the analysis (JL) does not have any chronic conditions. The authors will examine and discuss their preconceptions and beliefs surrounding the research questions, and consider the relevance of these preconceptions during each stage of analysis.

***Dissemination of information***. The review will be published in a peer-reviewed journal, reported using the ENTREQ guidelines ^[@ref-12]^. The review will also be presented at a relevant conference and disseminated to policy-makers, patients, and the public.

***Study status***. At time of publication the study is ongoing, and title and abstract screening is underway.

Discussion
==========

The review will add to the knowledge base of how financial burden affects patients with multimorbidity as well as informing potential policy and practice interventions for patients with multimorbidity. This review also forms part of a project which, as a whole, will contribute to developing guidance of how the specific needs of patients with multimorbidity are considered within clinical guidelines in Ireland, and internationally. The review will inform the development of a national survey that will quantify economic burden for patients with multimorbidity in Ireland. Limitations include the potential paucity of data in included studies.

Data availability
=================

Underlying data
---------------

No data are associated with this article

Extended data
-------------

Open Science Framework: The experience of financial burden for patients with multimorbidity: A protocol for a systematic review of qualitative research: Extended data. <https://doi.org/10.17605/OSF.IO/PN42R> ^[@ref-13]^

This project contains the following extended data:

-   Proforma.docx (a proforma with all headings under which study characteristics will be extracted)

-   Medline (OVID) Search strategy.docx (The mix of key words and mesh terms that will be used to search Medline and that will be transferred to other databases for searchers)

-   Grey literature search.docx (the list of websites that will be searched for grey literature using a variation of the Medline search strategy)

Reporting guidelines
--------------------

PRISMA-P checklist for 'The experience of financial burden for patients with multimorbidity: A protocol for a systematic review of qualitative research', <https://doi.org/10.17605/OSF.IO/PN42R> ^[@ref-18]^

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](http://creativecommons.org/publicdomain/zero/1.0/) (CC0 1.0 Public domain dedication).
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Version 2

The authors have addressed my previous comments, and I have no further improvements to suggest or clarifications to suggest.

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Research relevant to this review: Systematic review including metasynthesis, chronic and medically complex conditions in childhood.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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Version 1

*Is the rationale for, and objectives of, the study clearly described?*

Yes.

The rationale for the study is described. Something the authors may wish to consider is that the scope of the review is global, but the aim is to inform Irish guidelines: the review will include research from both Upper Income Country and Low and Middle Income Country settings. While the ambitious scope may potentially add value to the review, the authors could discuss how they plan to take account or acknowledge differences in setting, health care systems and access to healthcare.

*Is the study design appropriate for the research question?*

Yes.

This report is a protocol for a systematic review of qualitative research providing data on the experience of financial burden of patients with multiple morbidity. A completed PRISMA-P checklist for a systematic review protocol is attached and appropriately completed. There is a PROSPERO database registration which should facilitate publication of the completed review.

The methods are well described and appropriate but I do have a few questions and in places perhaps there could be further explanation/exposition.

A proposed search is clearly described in the supplementary materials but, given the broad scope of multimorbidity and its contexts, it would have been good to see more about how this search strategy was developed. Were scoping strategies used? Also, will the validity of the search be considered and if necessary adapted? Will the example search for Medline be tested and if necessary adapted for other databases?

A minor point is that a little more detail could be given on the inclusion criteria at the full text stage. I assume that all citations selected on the basis of title and abstract will undergo full text screening by two reviewers, with resolution by a third, this is not precisely the same as the citation screening process where one reviewer removes clearly irrelevant citations. A sentence explicitly stating the full text inclusion process would be helpful.

The suggested thematic analysis is appropriate, as is the process for generating codes and themes with validation from a second reviewer. Will first order data (direct quotations etc) be distinguished from second order data (author\'s interpretations) in reporting of the results? As you will potentially be including data from UMCs and LMICs and from settings with health systems that may differ markedly regarding co-payments and access to healthcare, how will you deal with these differences in the analysis. You might, for example, want to consider a thematic framework approach.

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Research relevant to this review: Systematic review including metasynthesis, chronic and medically complex conditions in childhood.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Larkin

James
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Dear Dr. Cummins,

Thank you for reviewing our submission and for your thoughtful feedback. Below are our responses. Text labelled 'reviewer' are the comments of the reviewer. Text labelled 'authors' is the response of the authors.

**Reviewer**: While the ambitious scope may potentially add value to the review, the authors could discuss how they plan to take account or acknowledge differences in setting, health care systems and access to healthcare.

**Authors:**Indeed, we anticipate there will be much variation in relation to setting and access in the included studies, which will have an impact on financial burden. We are using the GRADE CERQual tool to assess confidence in the review findings. This approach will allow us to take into account the impact of variation. Specifically, the 'relevance' section of the CERQual tool will incorporate an assessment of the extent to which the body of data from included studies is applicable to the context of the research question. To address this we have added sentences to clarify what each of the four domains assess (amended paragraph under 'Assessing the quality of the body of evidence').

Also, the table of included studies (which will be included as an appendix in the final publication) will include the country in which the study was carried out. This can be used for reference. In addition, the study characteristics, which will be described in the results, will outline the main countries in which the included studies were carried out.

**Reviewer**: It would have been good to see more about how this search strategy was developed. Were scoping strategies used? Also, will the validity of the search be considered and if necessary adapted? Will the example search for Medline be tested and if necessary adapted for other databases?

**Authors**: There was work done on this that we had not included. Thank you for drawing our attention to this. A paragraph (paragraph two under 'Search strategy') has been added to address the issues you have raised and provide more detail on the scoping search.

**Reviewer**: A sentence explicitly stating the full text inclusion process would be helpful.

**Authors**: Indeed, this was not clear from the original text. A sentence has been added (last sentence of paragraph one under 'screening')  to clarify which processes will be used for full text inclusion. 

**Reviewer**: Will first order data (direct quotations etc) be distinguished from second order data (author\'s interpretations) in reporting of the results?

**Authors**: First order data (direct quotations etc.) will be distinguished from second order data (author\'s interpretations) in reporting of the results. This will be done through the use italics for first order data. This has been made clear in the updated protocol (a new sentence has been added at the end of paragraph three under 'data extraction and analysis').

**Reviewer**: As you will potentially be including data from UMCs and LMICs and from settings with health systems that may differ markedly regarding co-payments and access to healthcare, how will you deal with these differences in the analysis. You might, for example, want to consider a thematic framework approach.

**Authors**: Dealing with the differences between countries does present a challenge. There are two areas within the CERQual tool, which will facilitate this: coherence and relevance. To clarify this we have added sentences to clarify what each of the four domains assess (amended paragraph under 'Assessing the quality of the body of evidence', added after sentence three).

In addition, within the analysis, if there are areas that are likely to be particularly effected by the health system then the countries in which the theme is applicable will be mentioned.
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Version 1

This is an interesting and much needed systematic review protocol. The aim is to synthesize the qualitative evidence relating to the experience of financial burden for people with multimorbidity. I have a few comments.

**Introduction**: The authors state that variations in estimated prevalence of multimorbidity are due to differences in settings and age groups. This is true but it is also due to differences in methods of measurement.Clinical guidelines are largely disease focussed but it would be worth mentioning the NICE multimorbidity guidelines 2016 ( <https://www.nice.org.uk/guidance/ng56>) which mentions treatment burden.There are several groups who have explored treatment burden in multimorbidity and it would be worth citing these:Eton DT, Ridgeway JL, Egginton JS, Tiedje K, Linzer M, Boehm DH *et al*.: **Finalizing a measurement framework for the burden of treatment in complex patients with chronic conditions.** *Patient Relat Outcome Meas* 2015, **6:** 117-126. ^[@rep-ref-26718-1]^Tran VT, Barnes C, Montori VM, Falissard B, Ravaud P: **Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions.** *BMC Med* 2015, **13:** 115. ^[@rep-ref-26718-2]^Sav A, Sav A, endall E, cMillan SS, elly F, hitty JA *et al*.: **\'You say treatment, I say hard work\': treatment burden among people with chronic illness and their carers in Australia.** *Health Soc Care Community* 2013. ^[@rep-ref-26718-3]^

**Methods:** Have the authors considered publishing the protocol on PROSPERO?Using one reviewer for initial exclusion during title screening should be acknowledged as a limitation, as this risks bias. One option would be to allow one reviewer to include studies at this stage but ideally two should be involved in exclusion.Will postal questionnaires be excluded? This should be added to the criteria.There is a potential for a large amount of papers to be full paper screened and included due to the fact that information on financial burden may be \'hidden\' in studies with other objectives e.g. those that aim to explore the experience of multimorbidity more generally. It may be useful to have a clear cut off for inclusion e.g. if there is one item of data on financial burden in a paper and the rest is irrelevant, will this paper be included?The methods for data analysis and quality appraisal appear very robust. 

Is the study design appropriate for the research question?

Yes

Is the rationale for, and objectives of, the study clearly described?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Reviewer Expertise:

Treatment burden, multimorbidity, stroke.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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